The interaction between hyaluronidase and hyaluronic acid gel fillers - a review of the literature and comparative analysis

Abstract

Hyaluronic acid (HA) is the most common component of aesthetic fillers. Many formulations exist, each exhibiting properties that are manifestations of individual molecular modifications. The enzyme hyaluronidase degrades hyaluronic acid and can therefore be injected into soft tissue to reduce suboptimally placed HA fillers or to reverse local ischemic complications. The clinically available varieties of hyaluronidase may be derived from crude animal extracts or genetically engineered from recombinant human DNA. Different HA fillers are not uniformly dissolved by a single source hyaluronidase, and hyaluronidase from different sources may have varying efficacy in the degradation of HA. Previous studies of subsets of HA fillers and hyaluronidases have provided limited and often conflicting data regarding these differences, and a more comprehensive scientific study is needed. In this review, the authors describe commonly available formulations of HA and hyaluronidase and review all studies of HA-hyaluronidase interaction available via a PubMed and Google Scholar search from 2005 to present, exploring trends in the data. Factors determined to confer increased resistance to degradation included higher concentration of HA, higher crosslinking density, and status as monophasic versus biphasic. Fillers of the Juvéderm family were generally found to be more resistant to degradation than members of the Restylane family. Results are less consistent for Belotero Balance. No variety of hyaluronidase was consistently superior at dissolving any variety of HA filler. More research is needed to clarify these clinically relevant relationships.

Keywords

Hyaluronic acid / hyaluronic acid gel / hyaluronidase / dermal fillers / enzymatic degradation / filler complications

References

[1] Farolch-Prats L.Facial contouring by using dermal fillers and botulinum toxin A: a practical approach..Aesthetic Plast Surg2019;43:793-802 PMCID:PMC6522458

[2] Jones D,Borrell M.In vitro resistance to degradation of hyaluronic acid dermal fillers by ovine testicular hyaluronidase..Dermatol Surg2010;36:804-9

[3] Urdiales-Galvez F,Figueiredo V,Mira M.Treatment of soft tissue filler complications: expert consensus recommendations..Aesthetic Plast Surg2018;42:498-510 PMCID:PMC5840246

[4] Cavallini M,Metalla M.The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers..Aesthet Surg J2013;33:1167-74

[5] Hylenex [Package insert].2012;San Diego, CAHalozyme Therapeutics, Inc

[6] Rao V,Woodward J.Reversing facial fillers: interactions between hyaluronidase and commercially available hyaluronic-acid based fillers..J Drugs Dermatol2014;13:1053-6

[7] Lambros V.The use of hyaluronidase to reverse the effects of hyaluronic acid filler..Plast Reconstr Surg2004;114:227

[8] Surek CC,Perry JD.Retrobulbar injection for hyaluronic acid gel filler-induced blindness: a review of efficacy and technique..Aesthetic Plast Surg2019;43:1034-40

[9] Hirsch RJ,Carruthers JDA.Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management of hyaluronidase..Dermatol Surg2007;33:357-60

[10] Paap MK,Ugradar S,Silkiss RZ.Examining the role of retrobulbar hyaluronidase in reversing filler induced blindness: a systemic review..Ophthalmic Plast Reconstr Surg2019;2020;36:231-8

[11] Paap MK,Ugradar S.Assessing retrobulbar hyaluronidase as a treatment for filler-induced blindness in a cadaver model..Plast Reconstr Surg2019;144:315-20

[12] Sall I.Comparison of the sensitivity of 11 crosslinked hyaluronic acid gels to bovine testis hyaluronidase..Polymer Degradation and Stability2007;92:915-9

[13] Gold MH.Use of hyaluronic acid fillers for the treatment of the aging face..Clinical Interventions in Aging2007;2:369-76 PMCID:PMC2685277

[14] Cavallini M,Trocchi G.Sensitivity of hyaluronic acid fillers to hyaluronidase: an in vitro analysis..J Clin Exp Dermatol Res2020;11:517

[15] Flynn TC,Hyun SH.Molecular weight, analyses and enzymatic degradation profiles of the soft-tissue fillers Belotero Balance, Restylane, and Juvederm Ultra..Plast Reconstr Surg2013;132:22S-32

[16] Shumate GT,Jones D,Hee CK.In vivo degradation of crosslinked hyaluronic acid fillers by exogenous hyaluronidases..Dermatol Surg2018;44:1075-83

[17] Buhren BA,Bolke E,Gerber PA.Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase..Eur J Med Res2018;23:37 PMCID:PMC6100712

[18] Juhasz MLW,Marmur ES.The kinetics of reversible hyaluronic acid filler injection treated with hyaluronidase..Dermatol Surg2017;43:841-7

[19] Dunn AL,Racz G.Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management..Expert Opin Biol Ther2010;10:127-31

[20] Weber GC,Schrumpf H,Gerber PA.Labrou N.Clinical applications of hyaluronidase..Therapeutic enzymes: function and clinical implications.2019;New YorkSpringer255-78

[21] Food and Drug Administration. Dermal Fillers Approved by the Center for Devices and Radiological Health. Available from: https://www.fda.gov/medical-devices/cosmetic-devices/dermal-fillers-approved-center-devices-and-radiological-health [Last accessed on 6 Jul 2020]

[22] Gold MH.What’s new in fillers in 2010?.J Clin Aesthet Dermatol2010;3:36-45 PMCID:PMC2945864

[23] Agerup B,Akermark C.Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis..BioDrugs2005;19:23-30

[24] Mansouri Y.Update on hyaluronic acid fillers for facial rejuvenation..Cutis2015;96:85-8

[25] Philipp-Dormston WG,Schuster B,Podda M.Evaluating perceived naturalness of facial expression after fillers to the nasolabial folds and lower face with standardized video and photography..Dermatol Surg2018;44:826-32 PMCID:PMC5976216

[26] U.S. National Library of Medicine. Study to Evaluate Satisfaction After Treatment with Kysse. Available from: https://clinicaltrials.gov/ct2/show/NCT03967444 [Last accessed on 24 Apr 2020]

[27] Allemann IB.Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds..Clin Interv Aging2008;3:629-34 PMCID:PMC2682392

[28] Monheit G,Hardas B,Weichman BM.Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds: results of a randomized, controlled study..Dermatol Surg2018;44:670-8 PMCID:PMC6221389

[29] Devgan L.Abstract: Juvéderm Volbella for use in periorbital volumization..Plast Reconstr Surg Glob Open2017;5:192-3 PMCID:PMC5636564

[30] Niforos F,Cavallini M,Chantrey J.VYC-12 injectable gel is safe and effective for improvement of facial skin topography: a prospective study..Clin Cosmet Investig Dermatol2019;12:791-8 PMCID:PMC6817835

[31] Prasetyo AD,Rubin MG,Nikolis A.Hyaluronic acid fillers with cohesive polydensfied matrix for soft-tissue augmentation and rejuvenation: a literature review..Clin Cosmet Investig Dermatol2016;9:257-80 PMCID:PMC5021061

[32] Palm MD.Filler frontier: what’s new and heading West to the US market..Semin Cutan Med Surg2014;33:157-63

[33] Lee A,Kriegel D.Hyaluronidase..Dermatol Surg2010;36:1071-7

[34] Landau M.Hyaluronidase caveats in treating filler complications..Dermatol Surg2015;41:S347-53

[35] Delorenzi C.Complications of injectible fillers, part I..Aesthet Surg J2013;33:561-75

[36] Vartanian AJ,Rubin MG.Injected hyaluronidase reduces Restylane-mediated cutaneous augmentation..Arch Facial Plast Surg2005;7:231-7